Cargando…
First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations wit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266014/ https://www.ncbi.nlm.nih.gov/pubmed/25512869 http://dx.doi.org/10.1186/2050-5736-2-11 |
_version_ | 1782348963936993280 |
---|---|
author | Magara, Anouk Bühler, Robert Moser, David Kowalski, Milek Pourtehrani, Payam Jeanmonod, Daniel |
author_facet | Magara, Anouk Bühler, Robert Moser, David Kowalski, Milek Pourtehrani, Payam Jeanmonod, Daniel |
author_sort | Magara, Anouk |
collection | PubMed |
description | BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies. METHODS: Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion. RESULTS: The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively. CONCLUSIONS: This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect. |
format | Online Article Text |
id | pubmed-4266014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42660142014-12-16 First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease Magara, Anouk Bühler, Robert Moser, David Kowalski, Milek Pourtehrani, Payam Jeanmonod, Daniel J Ther Ultrasound Research BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies. METHODS: Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion. RESULTS: The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively. CONCLUSIONS: This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect. BioMed Central 2014-05-31 /pmc/articles/PMC4266014/ /pubmed/25512869 http://dx.doi.org/10.1186/2050-5736-2-11 Text en Copyright © 2014 Magara et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Magara, Anouk Bühler, Robert Moser, David Kowalski, Milek Pourtehrani, Payam Jeanmonod, Daniel First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title | First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title_full | First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title_fullStr | First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title_full_unstemmed | First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title_short | First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease |
title_sort | first experience with mr-guided focused ultrasound in the treatment of parkinson's disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266014/ https://www.ncbi.nlm.nih.gov/pubmed/25512869 http://dx.doi.org/10.1186/2050-5736-2-11 |
work_keys_str_mv | AT magaraanouk firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease AT buhlerrobert firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease AT moserdavid firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease AT kowalskimilek firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease AT pourtehranipayam firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease AT jeanmonoddaniel firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease |